uniQure N.V. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $5.2 million (+40.4% year over year) and diluted EPS of -$0.88. It usually reports 29–61 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 1, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Mar 2, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–61 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
5
+40.4%
|
-61
+24.0%
|
-0.88
+36.2%
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
6
+11.0%
|
-81
-114.9%
|
-1.22
-76.8%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
4
+127.3%
|
-54
|
-0.85
-3.7%
|
|
Mar 2, 2026
61 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
6
+6.6%
|
-37
|
-0.60
+60.3%
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
4
+61.8%
|
-81
|
-1.38
-51.6%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
5
-52.7%
|
-38
|
-0.69
+40.5%
|
|
May 9, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
-81.5%
|
—
|
-0.82
+39.7%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
5
-21.9%
|
—
|
-1.50
+2.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QURE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Amsterdam
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1590560
- Former names
- uniQure B.V. (until Feb 6, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.